Gonzalo Rubio Paris

At Koa Health, we’ve made it our mission to leverage technology and research to create simple, personal, and accessible mental health support by combining evidence, cutting-edge tech, and user-centered design. We create breakthrough interventions backed by science with one clear goal: to improve people’s mental health. Designed to help your employees find the right mental healthcare at the right time, Koa Health’s comprehensive care model, Koa Care 360 offers employees simple navigation and personalized, evidence-based care built with the world’s leading clinician-academics. Koa Health provides an integrated approach to care that delivers mental health for everyone, whether they prefer digital-first care or would benefit from clinical services delivered by a human. Available to more than 3 million users worldwide, Koa Health addresses the full continuum of mental health needs – from prevention to treatment. Backed by leading investors such as Morningside, Ancora Finance Group, Wellington Partners Life Sciences, and MTIP, Koa Health leverages deep clinical expertise, research, and technology to deliver effective and accessible care that adapts to users’ unique circumstances, leading to lasting behavior change and positive health outcomes across the full continuum of mental health. Want to learn more about life at Koa Health? Visit our website at koahealth.com Our international team of behavioral scientists, developers, designers and health innovation leaders work, learn and grow together in a collaborative and inclusive culture. Want to learn more about life at Koa Health? Visit our website at koahealth.com

WE ARE CHANGING THE WAY PEOPLE BUY AND SELL HOMES Over the last 20 years, the Internet has changed the way we live, from booking travel to watching movies, and from paying taxes to banking. Online transactions are faster, cheaper to execute, more convenient, and generally more secure. Residential real estate, by contrast, remains stuck in a high-cost business model that pre-dates the Internet and remains stubbornly resistant to change. Harnessed properly, technology can help a lot – already, nearly 90% of consumers looking for a home go to sites like Zillow or Google to find and eventually select the properties that best suit their needs. We created REX in 2015 to bring residential real estate into line with today’s expectations by using AI and big data to push past the outmoded practices of traditional real estate brokers to provide a superior outcome for both buyers and sellers at one-third the cost. So how does REX do it? We use data modeling and machine learning to match sellers and buyers of homes as accurately and speedily as possible on Zillow, Google, Facebook, and more. And by doing that, we can reduce costs for all involved - REX covers both sides of the transaction instead of the 5-6% charged by traditional brokers. Unlike traditional brokers, REX licensed agents are salaried and incentivized to satisfy customers rather than to just close transactions in pursuit of a fast commission. Our team partners with sellers and buyers from listing to close, and shares with them the information they need via an easy-to-use web dashboard. REX is uniquely designed to simplify all of the moving parts, helping consumers with escrow, titling, service connections, mortgage and insurance shopping and keeps securely in the hands of the buyers and sellers all of the data related to the home and legal and financial information related to the transactions.

STALICLA SA is a Swiss clinical-stage biopharmaceutical company pioneering Neuro Precision Medicine in neurodevelopmental and neuropsychiatric disorders. With state-of-the-art technology platforms and clinical trials for Autism Spectrum Disorder (ASD) and Substance Use Disorder (SUD), STALICLA is changing the landscape of brain disease treatments. Neurodevelopmental Disorders: To propel neurodevelopmental research, STALICLA have identified patient subgroups and their matching candidate drugs within Autism Spectrum Disorder using its trailblazing, multi-omics DEPI platform. STALICLA is currently preparing Phase 2 trials for STP1, STALICLAs first patient subgroup-matched precision treatment. Substance Use Disorder research: STALICLA is working in partnership with the National Institute of Drug Abuse (NIDA) to advance Phase 3 clinical trials for the most clinically advanced drug candidate for cocaine abuse disorder, STP7. STALICLA is now raising series C funding to advance both verticals. For more information visit: https://stalicla.com.

Vectorious Medical Technologies develops novel treatment for heart failure patients which is based on physician directed, patients’ self-management paradigm. Leveraging its advanced, first of its kind, implantable V-LAP platform, which harvests valuable information from the heart’s left atrium, physicians and patients can monitor and manage disease status, prevent hospitalizations and improve quality of life. The V-LAP system is an investigational device which is currently under evaluation in multiple clinical studies in Europe, Israel and the U.S.

Vascular Graft Solutions (VGS), was founded in 2009 and is focusing on the development and commercialization of innovative solutions to improve the outcome of bypass surgeries. The company’s leading product, the VEST (Venous External Scaffolding Technology), is a novel external mechanical support for autologous vein grafts, intended for improving vein graft longevity. Pre-clinical and clinical studies confirmed that by restraining wall tension and improving lumen uniformity, the VEST optimizes vein graft hemodynamics and mitigates vein graft disease. Randomized controlled trials and real-world data studies in Europe, demonstrated the biomechanical effect of external stenting, its statistically significant mitigation of vein graft disease, and improved clinical outcomes.

Body Vision Medical is a commercial-stage medical device company specializing in AI-driven, real-time, intraoperative imaging. Body Visions FDA-cleared, CE-marked, ISO 13485 certified, and fully reimbursed LungVision™ platform addresses the unmet clinical need for diagnostics and treatment of lung cancer. LungVision has demonstrated superior clinical outcomes in over 2400 clinical procedures at leading lung centers across the globe. Leveraging 20 years of experience in lung cancer diagnostics, the LungVision platform transforms the way pulmonologists perform bronchoscopy, while significantly increasing the number of diagnostic procedures for early-stage lung cancer. LungVision is designed and developed from a deep understanding of the clinical need for a cost-effective, ground-up, unified and intelligence-driven platform, and integrates with existing equipment in the field of pulmonology, which has traditionally been underutilized. Through ongoing collaboration between physicians, clinical specialists, and engineers of different specialties, Body Vision continues to set a new standard of care for lung diagnostics. In addition to LungVision, Body Vision plans to introduce surgical markers for VATS or radiosurgery and, later, for minimally invasive treatment tools such as radio-frequency or microwave ablation. To learn more about Body Vision and its innovative medical solutions, please visit our website: www.bodyvisionmedical.com.

Laminate Medical Technologies is committed to advancing arteriovenous fistula (AVF) function for hemodialysis patients globally. Laminate’s flagship product, VasQ™, is an extravascular support designed to improve surgical fistula outcomes by providing permanent reinforcement to the artery-vein connection, promoting stability against wall tension, and decreasing turbulent flow. To learn more about VasQ, visit https://www.laminatemedical.com/.

At Amwell, we digitally empower our clients’ health care ambitions. It starts with our future-ready platform—a convergence of technologies, services, and devices that enables care delivery at scale, anytime and anyplace. But it’s not just products, it’s partnership. We connect providers, payers, and innovators, working alongside them to create an ecosystem of care that spans across in-person, virtual, and automated care. Powered by dedicated experts and industry-leading technology, we fulfill our commitment to reliable execution today and in the future. And behind everything we do is an unwavering pursuit of better outcomes for our clients. Together, we deliver on the bold promise of transforming care delivery and making care more accessible to all.

Amwell is a leading telehealth platform in the United States, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. With its belief that digital care delivery will transform healthcare, Amwell offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers telehealth solutions for over 130 health systems comprised of 2,000 hospitals and 55 health plan partners with over 7,000 employers, covering over 150 million lives. Amwell also has an affiliated, physician owned and operated medical practice that provides telehealth care exclusively on Amwell platforms. For more information on the Amwell Medical Group and to see how you can get involved as a provider, visit: https://www.linkedin.com/company/online-care-group/.

SPRIM Global Investments is a privately held investment company. SGI was established in 2008 following the global expansion of SPRIM Consulting & Services business. SPRIM Global Investments leverages the funnel of SPRIM’s sourcing, screening and selection processes across the globe to identify and invest in high potential health solutions. We find dynamic young companies proposing innovative offerings and help them to accelerate their growth. These startups can, in turn, leverage the SPRIM network, enabling them to fast-track their development. Our portfolio companies have full access to SPRIM’s fellow venture company experts across the globe as well as the company’s investment vehicles.

At Koa Health, we’ve made it our mission to leverage technology and research to create simple, personal, and accessible mental health support by combining evidence, cutting-edge tech, and user-centered design. We create breakthrough interventions backed by science with one clear goal: to improve people’s mental health. Designed to help your employees find the right mental healthcare at the right time, Koa Health’s comprehensive care model, Koa Care 360 offers employees simple navigation and personalized, evidence-based care built with the world’s leading clinician-academics. Koa Health provides an integrated approach to care that delivers mental health for everyone, whether they prefer digital-first care or would benefit from clinical services delivered by a human. Available to more than 3 million users worldwide, Koa Health addresses the full continuum of mental health needs – from prevention to treatment. Backed by leading investors such as Morningside, Ancora Finance Group, Wellington Partners Life Sciences, and MTIP, Koa Health leverages deep clinical expertise, research, and technology to deliver effective and accessible care that adapts to users’ unique circumstances, leading to lasting behavior change and positive health outcomes across the full continuum of mental health. Want to learn more about life at Koa Health? Visit our website at koahealth.com Our international team of behavioral scientists, developers, designers and health innovation leaders work, learn and grow together in a collaborative and inclusive culture. Want to learn more about life at Koa Health? Visit our website at koahealth.com

WE ARE CHANGING THE WAY PEOPLE BUY AND SELL HOMES Over the last 20 years, the Internet has changed the way we live, from booking travel to watching movies, and from paying taxes to banking. Online transactions are faster, cheaper to execute, more convenient, and generally more secure. Residential real estate, by contrast, remains stuck in a high-cost business model that pre-dates the Internet and remains stubbornly resistant to change. Harnessed properly, technology can help a lot – already, nearly 90% of consumers looking for a home go to sites like Zillow or Google to find and eventually select the properties that best suit their needs. We created REX in 2015 to bring residential real estate into line with today’s expectations by using AI and big data to push past the outmoded practices of traditional real estate brokers to provide a superior outcome for both buyers and sellers at one-third the cost. So how does REX do it? We use data modeling and machine learning to match sellers and buyers of homes as accurately and speedily as possible on Zillow, Google, Facebook, and more. And by doing that, we can reduce costs for all involved - REX covers both sides of the transaction instead of the 5-6% charged by traditional brokers. Unlike traditional brokers, REX licensed agents are salaried and incentivized to satisfy customers rather than to just close transactions in pursuit of a fast commission. Our team partners with sellers and buyers from listing to close, and shares with them the information they need via an easy-to-use web dashboard. REX is uniquely designed to simplify all of the moving parts, helping consumers with escrow, titling, service connections, mortgage and insurance shopping and keeps securely in the hands of the buyers and sellers all of the data related to the home and legal and financial information related to the transactions.

Akilia Partners is a global venture capital investment firm. We support entrepreneurs that visualize the future of their industries. We invest in the earlier stages of a company and follow on to support their growth. We search for new business models or differential technologies that solve specific problems in different industries. Flexible allocation, dedicated diligence & high conviction. Portfolio: Anabella, Assured Allies, BodyVision Medical, KOA Health, Laminate, Stalicla, Vascular Graft Solutions, Vectorious Medical Technologies, REX Homes, SPAN, Rappi, Lightspark Group.